Relationship Between Folic Acid and Warfarin Metabolism and Effect
Not Applicable
- Conditions
- Folic Acid Deficiency
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2008-10-29
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 400
- Registration Number
- NCT00162409
- Locations
- ๐ฎ๐ฑ
Hadassah Medical Organization, Jerusalem, Israel
Genetic Determinants of the Bronchodilatation Effect of Albuterol ex-Vivo
Not Applicable
- Conditions
- Asthma
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2008-10-29
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 150
- Registration Number
- NCT00162422
- Locations
- ๐ฎ๐ฑ
Hadassah Medical Organization, Jerusalem, Israel
Evaluation of CYP2C9 Activity
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 1200
- Registration Number
- NCT00162461
- Locations
- ๐ฎ๐ฑ
Hadassah Medical Organization, Jerusalem, Israel
Adoptive Immunotherapy for CMV Disease
Phase 1
Withdrawn
- Conditions
- CMV Disease
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 20
- Registration Number
- NCT00159055
- Locations
- ๐ฎ๐ฑ
Hadassah Medical Organization, Jerusalem, Israel
Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.
Phase 3
Completed
- Conditions
- Major DepressionBipolar DisorderUnipolar Depression
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2007-01-04
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 220
- Registration Number
- NCT00158990
- Locations
- ๐บ๐ธ
Global Medical Institutes, Princeton, New Jersey, United States
๐ฎ๐ฑHadassah Medical Organisation, Jerusalem, Israel
Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.
Phase 2
Withdrawn
- Conditions
- Metastatic Solid Tumors.
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2011-04-28
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 100
- Registration Number
- NCT00159016
- Locations
- ๐ฎ๐ฑ
Hadassah Medical Organization, Jerusalem, Israel
Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With Allogeneic Stem Cell Transplantation
Phase 2
Withdrawn
- Conditions
- Myelodysplastic SyndromesMyelofibrosis
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-04-28
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 24
- Registration Number
- NCT00148980
- Locations
- ๐ฎ๐ฑ
Hadassah Medical Organization, Jerusalem, Israel
Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.
Phase 2
Withdrawn
- Conditions
- Metastatic Solid Tumors
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 12
- Registration Number
- NCT00149019
- Locations
- ๐ฎ๐ฑ
Hadassah Medical Organization, Jerusalem, Israel
Treatment of Patients With Donor Lymphocytes Sensitized by Antigens Expressed by the Host
Phase 2
Withdrawn
- Conditions
- Hematological MalignancyNeoplasm Metastasis
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 50
- Registration Number
- NCT00149032
- Locations
- ๐ฎ๐ฑ
Hadassah Medical Organization, Jerusalem, Israel
Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors
Phase 1
Withdrawn
- Conditions
- Metastatic Solid Tumors
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 100
- Registration Number
- NCT00148993
- Locations
- ๐ฎ๐ฑ
The International Center for Cell Therapy & Cancer Immunotherapy (CTCI), Tel Aviv, Israel
ยฉ Copyright 2025. All Rights Reserved by MedPath